Schistosoma mansoni is a blood fluke parasite responsible for schistosomiasis. The best long-term strategy to control schistosomiasis is through immunization combined with drug treatment. In this study, we cloned, expressed and purified SmTSP-2 fused to the N-and C-terminal halves of Sm29 and tested these chimeras as vaccine candidates using an adjuvant approved to be used in humans.
Introduction
Schistosomiasis is one of the most important chronic parasitic diseases (1) . Currently, it is estimated 207 million people are infected with schistosomes distributed throughout 76 countries (2-3). The major intervention used to control the disease is treatment with the anthelmintic drug praziquantel, accompanied by the provision of safe water, adequate sanitation and, where possible, control of the
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snail intermediate host (1) (2) (4) (5) . Nevertheless, the current schistosomiasis control programs have particular limitations, particularly the fact that mass treatment does not prevent reinfection. The development of drug resistance by the parasite is also a concern that has to be considered (6) .
Likewise long-term effective disease control will benefit from the combination of vaccination and chemotherapy, plus sanitation and public health control measures (6) .
Vaccination against schistosomes can be targeted towards the prevention of infection and/or the reduction of parasite fecundity. A reduction in worm numbers is the "gold standard" for antischistosome vaccine development (7) . Therefore, using this "gold standard" methodology some of the most promising S. mansoni vaccine antigens discovered in the last years are the tegument proteins SmTSP-2 (8-9) and Sm29 (10) . Vaccination of mice with the recombinant protein SmTSP-2 formulated in Freund's adjuvant followed by challenge infection with S. mansoni resulted in reductions of 57%, 64% and 65-69% for adult worm burdens, liver egg burdens and fecal egg counts, respectively (9) . Additionally, vaccination with the recombinant Sm29 also formulated with Freund's adjuvant provided 51%, 60% and 50% reduction in adult worm burdens, intestinal eggs and in liver granuloma numbers, respectively (10) . Therefore, we combined these two molecules in a chimeric recombinant form to increase Sm29 solubility due to TSP-2 properties and to enhance protection efficacy induced by single antigen vaccination.
An interesting strategy to induce higher protection is the use of multivalent vaccines. Such a strategy is normally used in DNA vaccine studies, and induces higher protective efficacy than when the antigen is tested alone (11) (12) (13) . In an attempt of test a multivalent vaccine against schistosomiasis formulated with CpG-alum as adjuvant, we evaluated the protective effect of a SmTSP-2/Sm29 recombinant protein chimera in mice. Two recombinant proteins termed chimera A which present two predicted epitopes of Sm29 (SmTSP-2 plus the N-terminus of Sm29) and chimera B which present tree predicted epitopes of Sm29 (SmTSP-2 plus the C-terminus of Sm29) were produced and tested as potential candidate vaccines against S. mansoni infection. The epitopes were predicted using the computer program BCPREDS (14) . Mice immunized with both chimeras plus CpG-Alum adjuvant had reduced worm burden and liver pathology after challenge infection with S. mansoni.
Furthermore, sera from patients living in schistosomiasis endemic areas strongly recognized both recombinant chimeras A and B.
Materials and methods

2.1.Mice and parasites
Female C57BL/6 mice aged 6-8 weeks were purchased from the Federal University of Minas Gerais (UFMG) animal facility. Cercariae of S. mansoni (LE strain) were maintained routinely in Biomphalaria glabrata snails at CPqRR (Centro de Pesquisa René Rachou-Fiocruz) and prepared by exposing infected snails to light for 1 h to induce shedding. Cercarial numbers and viability were determined using a light microscope prior to infection. All protocols were approved by the Committee for Ethics in Animal Experimentation (CETEA) at Universidade Federal de Minas Gerais UFMG under permit 179/2010.
2.2.Cloning of the S. mansoni SmTSP-2/Sm29 cDNA
The chimeras SmTSP-2/Sm29A and SmTSP-2/Sm29B were cloned into a modified pET41a vector, within the N-terminal GST fusion protein replaced by SmTSP-2 EC-2 into the NdeI and KpnI restriction sites. The polymerase chain reaction (PCR) fragments corresponding to Sm29A (Nterminal Val27-Leu87) or Sm29B (C-terminal Cys88-Lys169) were cloned into the NcoI and XhoI sites of the modified pET41a plasmid generating the chimera A and chimera B, respectively. These constructs were transformed into Escherichia coli Rosetta-gami TM electrocompetent cells using the gene Pulser System TM (Bio-Rad). E. coli transformants harboring the plasmids were screened on LB agar plates containing kanamycin (50 μg/ml), chloramphenicol (34 μg/ml) and tetracycline (12.5 μg/ml). DNA sequencing was performed to confirm the presence and the correct orientation of the chimeras' open reading frames.
2.3.Expression and purification of the recombinant chimera A and B
Chimeras A and B were expressed in E. coli with an in-frame 6x-histidine C-terminal tag using the pET41a expression vector. An E. coli Rosetta-gami (DE3) culture containing the recombinant plasmid was grown at 30 o C to an optical density of approximately 0.5-0.8 at 600nm and gene expression of both chimeras was induced using 1 mM IPTG. After 16 hours of induction, the bacterial cells were harvested by centrifugation at 4,000 g for 20 min. The pellet was resuspended in 50 ml of 10 mM
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SDS-PAGE and immunoblotting
SDS-PAGE of purified chimeras A and B were performed (15) and the gel electroblotted onto nitrocellulose membrane (16) . The membrane was then blocked with TBST (0·5 M NaCl−0·02 M Tris (pH 7·5), 0·05% Tween 20) containing 5% non-fat dry milk for 16 hrs at room temperature.
Subsequently, the membrane was incubated in a 1:2000 dilution of anti-6xHIS antibodies (GE Healthcare) in TBST for 1 hr at room temperature. After three washes using TBST, the membrane was incubated in 1:2000 mouse IgG conjugated with alkaline phosphatase (AP) and treated with AP reaction developing buffer containing nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-1-phosphate (BCIP). After the reaction was developed, the membrane was washed using distilled water and dried on filter paper.
Mice Immunization
Six to eight week-old female C57BL/6 mice were divided into four groups of ten mice each. Mice were subcutaneously injected in the nape of the neck with 100 μl containing 25 μg of chimera A, chimera B, Sm29 alone or PBS plus adjuvant as a control group at days 0, 15 and 30 as previously reported by our group (10, 17) . The recombinant protein and the control group was formulated with 20 μg of CpG (10104)-Alum (Sigma) as adjuvant.
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Challenge infection and worm burden recovery
Fifteen days after the last boost, mice were challenged through percutaneous exposure of abdominal skin for 1 h in water containing 100 cercariae (LE strain). Forty-five days after challenge, adult worms were perfused from the portal veins (18) . Two independent experiments were performed to determine protection levels. The protection was calculated by comparing the number of worms recovered from each vaccinated group with its respective control group, using the formula:
Where PL = protection level, WRCG = worms recovered from control group, and WREG = worms recovered from experimental group.
2.7.Measurement of specific antibodies
Following immunization, sera of ten mice from each vaccinated or control group were collected at two-week interval. Measurements of specific antibodies IgG, IgG1 and IgG2a to each immunized group were performed using indirect ELISA. Maxisorp 96-well microtiter plates (Nunc, Denmark)
were coated with 5 µg/ml of each protein (chimera A, chimera B and Sm29) in carbonatebicarbonate buffer, pH 9.6 for 16 hrs at 4 o C, then blocked for 2 hrs at room temperature with 200 µl/well PBST (phosphate buffer saline, pH 7.2 with 0.05% Tween-20) plus 10% FBS (fetal bovine sera). One hundred microliters of each serum from the chimera A, chimera B and Sm29 immunized group was diluted 1:100 in PBST and added per well in plates previously sensitized with the proteins chimera A, chimera B and Sm29, respectively.
Plate-bound antibody was detected by peroxidase-conjugated anti-mouse IgG, IgG1 and IgG2a
(Sigma) diluted in PBST 1:10000, 1:5000 and 1:2000, respectively. Antigen concentration and the dilutions of mouse serum and secondary antibodies were optimized as previously described (17) (18) . 
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Cytokine analysis
Cytokine experiments were performed using splenocyte cultures from individual mice immunized with chimera A, chimera B, or PBS plus CpG-Alum as control (n=4 for each group). Splenocytes were isolated from macerated spleens of individual mice one week after the third immunization and washed twice with sterile PBS as previously described (17) (18) . After washing, the cells were adjusted to 1x10 6 cells per well for IL-4, IFN-γ and TNF-α assays in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS, 100 U/ml of penicillin G sodium, 100 µg/ml of streptomycin sulfate, 250 ng/ml of amphotericin B. Splenocytes were maintained in culture with medium alone or stimulated with the recombinant proteins chimera A and B (25 µg/ml) or with concanavalin A (ConA) (5 μg/mL) for IL-4 and IFN-γ, and LPS (1 μg/mL) for TNF-α, as positive controls (17) (18) . In order to neutralize potential effects of LPS presented in the S. mansoni recombinant antigens (chimera A-2.84 EU/ml, chimera B-2.85 EU/ml), Polymyxin B (Calbiochem, Germany; 10 μg/mL) was added to cell cultures every 12 hours during all culture period (19) . The 96-well plates (Nunc) were maintained in an incubator at 37 o C with 5% CO2. The assays for measurement of IL-4, IFN-γ and TNF-α were performed using the Duoset ELISA kit (R&D Diagnostic, Minneapolis, MN)
according to the manufacturer's directions.
Study population
Serum was obtained from individuals living in two different endemic areas for schistosomiasis ("Melquiades" and "Côrrego do Onça", Minas Gerais, Brazil). These individuals were classified in five groups, regarding their infection status and the selection of subjects was performed based only on the criteria for inclusion and exclusion of each group independent of previous knowledge of immune responses for each individual. Non-infected (NI) individuals, natural resistant (NR), infected (INF), resistant (RR) and susceptible (SR) to S. mansoni reinfection as described in Table 1 . Individuals classified as susceptible to S. mansoni reinfection (SR) showed stool-positive examination following treatment (praziquantel, 40 mg/kg). The sera from RR and SR groups were obtained six months after praziquantel treatment and these individuals were examined for S. mansoni infection using the Kato-Katz technique before treatment and one, six and 12 months after treatment to check for reinfection rates. The water contact exposure was objectively evaluated by observers and NR, SR and RR groups had at least one contact daily. These individuals were followed for 24 months.
Additionally, RR, SR and INF patients were negative for other helminthic infections. These patients or
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their legal guardians gave informed consent after explanation of the protocol that had been previously approved by the Ethical Committee of the Federal University of Minas Gerais.
Measurement of human humoral responses of patients living in endemic areas for schistosomiasis
Sera of schistosomiasis patients living in endemic and non-endemic areas in Brazil were used in an ELISA (20) to measure the levels of total IgG to chimera A or chimera B. The studied population was divided into NI, SR, NR, RR and INF subjects ( Table 1) . Levels of total IgG to Sm29, chimera A and chimera B antigens were assessed using 96 well flat-bottom microtiter plates (Nunc) that were coated overnight at 4°C with 100 µl of each recombinant protein at a concentration of 5 µg/ml in 0.1 M carbonate bicarbonate buffer (pH 9·6) per well. The plates were then blocked with 10% bovine fetal serum in PBS (pH 7·4) for 2 h at room temperature. Subsequently, the plates were washed three times with PBS plus 0.05% Tween-20 (PBST). For total IgG, serum samples were diluted 1:50 in PBST (100 µl/well added in duplicate) and the plates incubated for 1 h at room temperature.
Peroxidase-labeled anti-human IgG (Sigma, St Louis, MO) was added at dilutions of 1:10000 (100 µl/well). After 1 h at 37°C, the plates were washed and orthophenyl-diaminobenzidine plus 0.05% hydrogen peroxide in phosphate citrate buffer (pH 5) was added (100 µl/well). The plates were then incubated for 30 min at room temperature, and the reaction was stopped by addition of 5% H 2 SO 4
(50 µl/well). Absorbance was read at 492 nm using a microplate reader (Bio-Rad, Hercules. CA, USA). counterstained with Harris' Haematoxylin as previously described (21) . The area from each liver section (mm 2 ) was calculated using the KS300 software connected to a Carl Zeiss image analyzer. For measurements of the total area of granulomas, 20 granulomas with a single well-defined egg from each animal of a group of eight mice were randomly selected and assessed using a microscope with
Histopathological analysis
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10× objective lens. Granuloma images were obtained through a JVC TK-1270/RBG microcamera.
Using a digital pad in the KS300 software built in a Carl Zeiss image analyzer, the areas were measured and expressed in square micrometers (μm 2 ).
Statistical analysis
Statistical analysis was performed with Student's t-test using the software package GraphPad Prism (La Jolla, CA, USA). Kruskal-Wallis test was used to compare the levels of IgG induced by the different patient groups.
Results
3.1.Production of recombinant chimera A and B
Chimeras A and B were expressed as inclusion bodies and purified under denaturing conditions 
3.2.Antibody profile following mice immunization
In order to evaluate the profile of the humoral immune response, total IgG and the subclasses IgG1 and IgG2a to Sm29, chimera A and B, were measured from sera of ten vaccinated and control animals. All vaccinated mice developed significant levels of specific IgG, IgG1 and IgG2a antibodies after the second immunization compared to the non-vaccinated control group and these levels increased significantly after the third immunization for all tested antigens. Mice immunized with chimera B (SmTSP-2 fused to Sm29 C-terminus) showed significantly higher titers of IgG and IgG2a isotypes compared to Sm29 or chimera A antigens (Figure 2 ).
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Cytokine profile
To evaluate the cytokine profile generated by the immunization of mice with chimera A and chimera B, splenocytes were isolated from vaccinated and control animals after the third immunization.
Statistically significant levels of IFN-γ and TNF-α were detected in splenocyte culture supernatants of chimera A and chimera B vaccinated mice compared to the control group (Figure 3) . Chimera A immunization induced higher production of IFN-γ (712.7 ± 261.4 pg/ml) and TNF-α (407 ± 94.3 pg/ml) compared to chimera B immunized group (IFN-γ 328.8 ± 113.7 pg/ml; TNF-α 259 ± 38.9 pg/ml). Additionally, no significant amounts of IL-4, a signature of Th2-immune responses, were detected. These results show that immunization with chimeras A and B induces a Th1 type of immune response in mouse T cells, characterized by the production of IFN-γ and TNF-α cytokines.
The results of splenocyte stimulation with the positive controls ConA and LPS are not shown but induced high levels of these cytokines as expected.
Worm burden recovery
Protective immunity induced by vaccination with recombinant Sm29, and chimeras A and B were evaluated 45 days after challenge with 100 S. mansoni cercariae. Mice vaccinated with recombinant Sm29 (20.36%), chimera A (27.84%) and B (34.83%) showed statistically significant reduction in worm burden recovery compared to control mice (Table 2) .
Immunization with chimeras A or B induces reduction in liver pathology
Histological analysis by digital morphometry of picrosirius-stained sections obtained from mice immunized with recombinant Sm29, chimera A or chimera B showed reductions of 38%, 48% and 31% on granuloma area, respectively. These findings demonstrated that all antigens tested are important molecules involved in reduction of liver pathology (Figure 4 ).
Human IgG responses to chimera A and B
To investigate the presence of specific anti-Sm29, anti-chimera A or anti-chimera B antibodies in sera of individuals living in schistosomiasis endemic area ELISA was performed. Total IgG levels in sera of schistosomiasis patients and non-infected individuals were evaluated. The NR, INF and RR groups
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studied had higher levels of IgG anti-chimera A or anti-chimera B compared to the non-infected group ( Figure 5 ). In order to determine whether IgG responses to chimera A or chimera B could differentiate resistant versus susceptible individuals, we compared the NR group to INF individuals, and RR patients compared to the SR group. The RR patient group produced elevated levels of IgG to all antigens tested in this study when compared to the SR patient group. In contrast, the NR group did not show statistically significant higher levels of IgG to chimeras A or B when compared with the INF group. However, the level of specific anti-Sm29 IgG was significantly higher in the NR group when compared to INF subjects. Additionally, the RR group showed higher IgG levels against chimeras A and chimera B when compared to Sm29. These results demonstrate that the fusion proteins are better recognized by human total IgG of patients with resistant phenotype compared to Sm29 alone.
Discussion
Schistosomiasis is a chronic debilitating parasitic disease that represents a major health problem in endemic areas, such as various parts of South America, Africa, and Southeast Asia (22) . Currently, chemotherapy is the major control strategy used, however, extension of endemic areas and constant reinfection of individuals, together with poor sanitary conditions in tropical countries makes drug treatment inefficient (23) (24) . Therefore, complementary control measures, including vaccines could contribute enormously to disease control (25) (26) (27) . Tegument proteins are of great importance to schistosome vaccine development since they are a major host-parasite interface (28) (29) . Recently, many tegument proteins were identified and characterized including the recombinant proteins SmTSP-2 and Sm29. Previously, it was demonstrated that the large extracellular loop of the S. mansoni tegument tetraspanin, SmTSP-2, formulated with Freund's adjuvant, is an efficacious vaccine antigen, eliciting high levels of protection in a murine schistosomiasis model of infection (9, 30) . SmTSP-2 vaccine antigen is also protective, even when formulated with CpG-alum (30). Sm29 recombinant protein fused to 6xHIS and used to vaccinate C57BL/6 formulated with Freund's adjuvant showed a reduction of 51% in the number of adult worms, and induced a Th1 immune response in vaccinated mice (6, 10) . Furthermore, a preparation containing GPI-anchored proteins, Sm29 plus other molecules engendered a mixed Th1/Th2 type of immune response in mice, which conferred partial protection against cercariae challenge and reduced pathology in the liver (31) .
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In the present study, we show that it is possible to induce protection in a murine schistosomiasis model of infection using the recombinant proteins SmTSP-2 and Sm29 in chimeric forms when formulated with CpG-alum, a human-approved adjuvant. C57BL/6 mice immunized with chimeras A and B in the presence of CpG-alum showed high levels of specific IgG, IgG1 and IgG2a that appeared after the second immunization. Regarding IgG1 and IgG2a subclasses, specific IgG1 against both chimeras was predominant. However, chimera B induced the highest levels of IgG and IgG2a compared to chimera A or Sm29 alone. Several S. mansoni antigens tested by our group that had a tendency to induce a Th2 type of immune response failed to engender protection in the mouse model (17, 34) . In contrast, Th1 antigens induced partial protection against infection (10, 18, 35) .
In this study, we show that the chimeric proteins A and B are protective, even when formulated with a human-approved adjuvant combination. Previous studies have demonstrated that vaccination with recombinant Sm29 and SmTSP-2 formulated with Freund's adjuvant provided reduction in worm burden and liver pathology (9) (10) . Herein, the association of SmTSP-2 fused to Sm29 vaccine, in a chimeric form, not only reduced parasite load but also the pathology and disease associated with schistosomiasis compared to control group that received PBS formulated with CpG-alum.
However, when the results of vaccination with the two chimeric forms (A and B) were compared to Sm29 alone we did not detect statistically significant differences in worm burden and liver pathology among these groups.
This article is protected by copyright. All rights reserved. (36) . Therefore, the recognition of antigens by IgG isotypes in individuals resistant to infection and reinfection is an important step in evaluation of the potential of these antigens as schistosome vaccine candidates.
In conclusion, chimera A and chimera B immunization induced a Th1 type of immune response, worm burden reduction and diminished liver pathology in murine schistosomiasis compared to control group that received PBS with adjuvant. Both chimeras were recognized by sera from natural resistant human subjects, and presented higher IgG levels in subjects resistant to reinfection compared to Sm29 alone, reinforcing earlier studies on the role of these antigens as targets of naturally acquired immunity to schistosomiasis and the potential of these chimeric proteins in the development of an effective anti-schistosomiasis vaccine better than Sm29 formulated alone. Western blot analysis of the purified recombinant protein using anti-6xHIS antibody. Results are presented as the mean absorbance measured at 492 nm for each group. Results represent the mean of two independent experiments. Statistically significant differences between responses to Sm29, chimera A and chimera B compared to control group are denoted by an asterisk and statistically significant differences of chimera B compared to Sm29 and chimera A are denoted by two asterisks for p<0.05. 
